The Asthma App as a New Way to Promote Responsible Short-Acting Beta2-Agonist Use in People With Asthma: Results of a Mixed Methods Pilot Study
JMIR Human Factors · 2024
DOI: 10.2196/54386 ↗Kurz gefasst
Mixed-Methods-Studie in der Zeitschrift JMIR Human Factors, 2024. Verfasst von Liselot N van den Berg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands. Hauptthemen laut MEDLINE: Asthma, Drug-Related Side Effects and Adverse Reactions, Mobile Applications, Rhinitis, Allergic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Approximately 262 million people worldwide are affected by asthma, and the overuse of reliever medication—specifically, short-acting beta2-agonist (SABA) overuse—is common. This can lead to adverse health effects. A smartphone app, the Asthma app, was developed via a participatory design to help patients gain more insight into their SABA use through monitoring and psychoeducation.
Objective
This pilot study aims to evaluate the feasibility and usability of the app. The preliminary effects of using the app after 3 months on decreasing asthma symptoms and improving quality of life were examined.
Methods
A mixed methods study design was used. Quantitative data were collected using the app. Asthma symptoms (measured using the Control of Allergic Rhinitis and Asthma Test) and the triggers of these symptoms were collected weekly. Quality of life (36-Item Short-Form Health Survey) was assessed at baseline and after 3, 6, and 12 months. User experience (System Usability Scale) was measured at all time points, except for baseline. Furthermore, objective user data were collected, and qualitative interviews, focusing on feasibility and usability, were organized. The interview protocol was based on the Unified Theory of Acceptance and Use of Technology framework. Qualitative data were analyzed using the Framework Method.
Results
The baseline questionnaire was completed by 373 participants. The majority were female (309/373, 82.8%), with a mean age of 46 (SD 15) years, and used, on average, 10 SABA inhalations per week. App usability was rated as good: 82.3 (SD 13.2; N=44) at 3 months. The Control of Allergic Rhinitis and Asthma Test score significantly improved at 3 months (18.5) compared with baseline (14.8; β=.189; SE 0.048; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands.
- National eHealth Living Lab, Leiden, Netherlands.
ORCID-Profile: Liselot N van den Berg, Cynthia Hallensleben, Lisa Ae Vlug, Niels H Chavannes, Anke Versluis
Zitieren
APA
van den Berg, L. N., Hallensleben, C., Vlug, L. A., Chavannes, N. H., & Versluis, A. (2024). The Asthma App as a New Way to Promote Responsible Short-Acting Beta2-Agonist Use in People With Asthma: Results of a Mixed Methods Pilot Study. JMIR Human Factors. https://doi.org/10.2196/54386
Vancouver
van den Berg LN, Hallensleben C, Vlug LA, Chavannes NH, Versluis A. The Asthma App as a New Way to Promote Responsible Short-Acting Beta2-Agonist Use in People With Asthma: Results of a Mixed Methods Pilot Study. JMIR Human Factors. 2024. doi:10.2196/54386
BibTeX
@article{vandenBerg2024,
author = {van den Berg, Liselot N and Hallensleben, Cynthia and Vlug, Lisa Ae and Chavannes, Niels H and Versluis, Anke},
title = {The Asthma App as a New Way to Promote Responsible Short-Acting Beta2-Agonist Use in People With Asthma: Results of a Mixed Methods Pilot Study},
journal = {JMIR Human Factors},
year = {2024},
doi = {10.2196/54386}
}
EUVIMED